FDA Okays Treatment For Increasing Pain-free Light Exposure

The U.S. Food and Drug Administration has approved Clinuvel Pharmaceuticals' treatment Scenesse for a rare genetic disorder that induces skin damage from exposure to light. The FDA said it approved the use of Scenesse (afamelanotide) to treat erythropoietic protoporphyria or EPP, a rare genetic disorder characterized by an extreme risk of severe burns or phototoxicity of the skin.

from RTT - Biotech https://ift.tt/33mJuzn
via IFTTT